Vortioxetine in the routine management of major depressive disorder: an analysis of European automated healthcare databases
In this European healthcare database study, the extent and characteristics of vortioxetine use were in line with clinical trial experience and the current label. Analyses of events, including those of special interest, did not raise any new safety concerns.
Authors
- María Rubio-Valera (ORCID: https://orcid.org/0000-0003-2856-1697)
- Eline Houben (ORCID: https://orcid.org/0000-0002-9173-3335)
- Fernie Penning-van Beest
- Frank Andersohn (ORCID: https://orcid.org/0000-0003-3514-9238)
- Elin Heldbo Reines (ORCID: https://orcid.org/0000-0002-1151-9102)
- Michael Cronquist Christensen (ORCID: https://orcid.org/0000-0002-3605-7223)
- Katja M. Hakkarainen
- Ignacio Aznar‐Lou (ORCID: https://orcid.org/0000-0002-6780-5968)
- Pilar Hernández
- Lambert Creuwels
Institutions
- Lundbeck (Denmark) (DK)
- PAREXEL International (United Kingdom) (GB)
- IQVIA (United Kingdom) (GB)
- Pharmo Institute (NL)
- IQ Solutions (US)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1080/03007995.2025.2505692
- Citations
- 2
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 2.79